Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies

Passaro, Antonio; Peters, Solange

doi:10.1200/jco.23.00013

Cited by 42 publications

(7 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of specific monoclonal antibodies (mAbs) with a cytotoxic effect of a conjugated payload proofed to be effective in previous studies 164 . In this setting, several ADCs are being developed and studied in different combinations in both first-and second-line treatment 161 , such as HER-2, HER-3, trophoblast cell surface antigen 2 (TROP2), c-MET, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), and B7-H3 165 .…”

Section: The Optimal Treatment Strategy and Subsequent Therapiesmentioning

confidence: 99%

Fifteen years of precision medicine in the lung cancer management: Perspectives and Challenges

Ferreira,

Marchi,

Veloso

et al. 2024

MRAJ

View full text Add to dashboard Cite

Precision medicine has revolutionized lung cancer management – particularly non-squamous cell carcinomas – with a broader genomic comprehension and the possibility of offering tailored treatments guided by oncogenic driver mutations – the basis of precision medicine. Since the publication of the IPASS trial in 2009 a new Era of molecular actionability began for lung cancer research and treatment. The remarkable past fifteen years were characterized by advances on genomic testing methodologies, the emergence of new biomarkers and targeted therapies, and the widespread of precision medicine in lung cancer care from advanced to earlier stages – specially for the adenocarcinoma histology, a heterogeneous disease with unprecedent improvements in outcomes. Nonetheless, several barriers need to be overcome with the adoption of cutting-edge technologies, such as the high cost of new diagnostic and therapeutical technologies and their discrepant accessibility, mainly in low- and middle-income countries. Moreover, there is still a lack of clear clinical actionability for squamous cell carcinoma and small cell lung cancer in which ideal biomarkers are yet to be discovered and validated. Herein, we aimed to discuss several aspects on how precision medicine positively impacted on lung cancer management and the lessons learned. Additionally, we scoped future perspectives on precision oncology in lung cancer as technology advances.

show abstract

Section: The Optimal Treatment Strategy and Subsequent Therapiesmentioning

confidence: 99%

Fifteen years of precision medicine in the lung cancer management: Perspectives and Challenges

Ferreira,

Marchi,

Veloso

et al. 2024

MRAJ

View full text Add to dashboard Cite

show abstract

“…In thoracic oncology, the development of antibody drug conjugates (ADCs) has led to new treatment options for NSCLC and small-cell lung cancer [ 25 , 29 ], with associated predictive biomarkers [ 25 – 29 ]. These biomarkers (such as c-MET, TROP2, CEACAM5, DLL3, HER3, HER2, and B7-H3) can be identified using IHC or molecular tests [ 27 , 30 , 31 ].…”

Section: Molecular Biomarkers For Lung Cancersmentioning

confidence: 99%

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

Hofman,

Berezowska,

Kazdal

et al. 2023

Virchows Arch

View full text Add to dashboard Cite

The continuing evolution of treatment options in thoracic oncology requires the pathologist to regularly update diagnostic algorithms for management of tumor samples. It is essential to decide on the best way to use tissue biopsies, cytological samples, as well as liquid biopsies to identify the different mandatory predictive biomarkers of lung cancers in a short turnaround time. However, biological resources and laboratory member workforce are limited and may be not sufficient for the increased complexity of molecular pathological analyses and for complementary translational research development. In this context, the surgical pathologist is the only one who makes the decisions whether or not to send specimens to immunohistochemical and molecular pathology platforms. Moreover, the pathologist can rapidly contact the oncologist to obtain a new tissue biopsy and/or a liquid biopsy if he/she considers that the biological material is not sufficient in quantity or quality for assessment of predictive biomarkers. Inadequate control of algorithms and sampling workflow may lead to false negative, inconclusive, and incomplete findings, resulting in inappropriate choice of therapeutic strategy and potentially poor outcome for patients. International guidelines for lung cancer treatment are based on the results of the expression of different proteins and on genomic alterations. These guidelines have been established taking into consideration the best practices to be set up in clinical and molecular pathology laboratories. This review addresses the current predictive biomarkers and algorithms for use in thoracic oncology molecular pathology as well as the central role of the pathologist, notably in the molecular tumor board and her/his participation in the treatment decision-making. The perspectives in this setting will be discussed.

show abstract

“…In normal tissues, B7-H3 is either not expressed or has low expression levels. However, in the context of NSCLC, there is a notable increase of B7-H3 expression in tumor tissues, making it a potential evaluative indicator for unfavorable prognosis [17,18]. Studies have demonstrated the correlation between the expression levels of B7-H3 in tumor tissues and clinical parameters such as lymph node metastasis and tumor, node and metastasis staging in patients diagnosed with lung cancer [18].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic value of serum soluble B7-H3 in nonsmall cell lung cancer

Li,

Xu,

et al. 2024

Anti-Cancer Drugs

View full text Add to dashboard Cite

The aim of this study was to investigate the utility of serum soluble B7-H3 (sB7-H3) as a diagnostic marker for early-stage nonsmall cell lung cancer (NSCLC) and its potential for evaluating the prognosis of patients with advanced-stage NSCLC. In this study, an ELISA was employed to detect the expression levels of sB7-H3 in a cohort of patients diagnosed with NSCLC (n = 122) and a control group (n = 42) during the same observation period. Comparative analyses were conducted to ascertain the variations in sB7-H3 concentrations between the NSCLC cohort and the healthy control group, as well as across pathological types and the presence and absence of lymph node metastasis. (1) The concentration of sB7-H3 in patients diagnosed with NSCLC exhibited a statistically significant increase compared to that observed in the healthy control group (P < 0.05). Elevated expression levels of sB7-H3 demonstrated a significant correlation with pathological type, lymph node metastasis, tumor, node and metastasis stage and programmed cell death ligand (PD-L1) expression (P < 0.05). (2) The diagnostic utility of sB7-H3 for the diagnosis of NSCLC and the heightened expression of PD-L1 demonstrated high levels of sensitivity and specificity. (3) Elevated levels of sB7-H3 emerged as an independent risk factor impacting the overall survival of patients diagnosed with advanced NSCLC. The findings of this study suggest that sB7-H3 holds promise as a diagnostic tool for early-stage NSCLC. The elevated expression of sB7-H3 appears to serve as a reliable indicator for assessing the prognosis of patients diagnosed with advanced NSCLC.

show abstract

Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies

Cited by 42 publications

References 138 publications

Fifteen years of precision medicine in the lung cancer management: Perspectives and Challenges

Fifteen years of precision medicine in the lung cancer management: Perspectives and Challenges

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

Diagnostic and prognostic value of serum soluble B7-H3 in nonsmall cell lung cancer

Contact Info

Product

Resources

About